Conatus Pharmaceuticals (CNAT) Reports In-Line Q1 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. DOX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. CVI

Go back to Conatus Pharmaceuticals (CNAT) Reports In-Line Q1 EPS

Conatus Pharmaceuticals Reports First Quarter 2015 Financial Results and Program Updates

May 7, 2015 4:02 PM EDT

Meeting with FDA Provides Clarity on Initial Emricasan Registration Pathway in NASH Cirrhosis

Evaluating Expansion of Registration Strategy to Include NASH Fibrosis

SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2015, and provided updates on its initial registration pathway and clinical development programs.

Financial Results

The net loss was $6.0... More